TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have shown promising clinical efficacy in non-squamous non-small cell lung cancer (NSCLC); however, resistance is frequently observed in malignant cells, operating through a mechanism that remains largely unknown...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ying, Yang, Zhiwei, Li, Weijie, Xu, Shudi, Wang, Tao, Wang, Ting, Niu, Mengjie, Zhang, Shengli, Jia, Lintao, Li, Shengqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872746/
https://www.ncbi.nlm.nih.gov/pubmed/26745678
http://dx.doi.org/10.18632/oncotarget.6826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872746/
https://www.ncbi.nlm.nih.gov/pubmed/26745678
http://dx.doi.org/10.18632/oncotarget.6826

Ejemplares similares